A Phase 2 Randomized, Double-Blind, Multicenter Trial of Amplimexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy Naïve Pancreatic Adenocarcinoma (Stage IV).

Trial Profile

A Phase 2 Randomized, Double-Blind, Multicenter Trial of Amplimexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy Naïve Pancreatic Adenocarcinoma (Stage IV).

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Nov 2010

At a glance

  • Drugs Gemcitabine; Imexon
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AmpliMed
  • Most Recent Events

    • 10 Jul 2010 Disappointing results have been presented in an AmpliMed media release. Based on these results it is unlikely AmpliMed will continue onto phase III clinical trials with imexon in pancreatic cancer.
    • 10 Jul 2010 Status changed from active, no longer recruiting to completed.
    • 10 Jul 2010 Primary endpoint 'Overall survival' has not been met, according to an AmpliMed media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top